Market Overview

UPDATE: Auriga Raises PT to $57 on JAZZ Pharmaceuticals


Auriga raises its price target on Buy-rated JAZZ Pharmaceuticals (NASDAQ: JAZZ) to $57 from $55 as the company posted another consensus-beating quarter.

Auriga says, "We remain impressed by Jazz's execution, as the company had another quarter of record revenue and EPS. The company also closed the Azur Pharma acquisition ahead of schedule, and we view 2012 guidance as being conservative. With its efficient tax structure and outstanding business execution, we think Jazz is well positioned to grow via M&A, a strategy used successfully by Valeant Pharmaceuticals."

JAZZ closed at $50.55 a share on Monday.

Posted-In: AurigaAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (JAZZ)

View Comments and Join the Discussion!

Partner Center